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Three structurally related oxathiolone fused chalcone derivatives appeared effective
chemosensitizers, able to restore in part sensitivity to fluconazole of multidrug-resistant
C. albicans strains. Compound 21 effectively chemosensitized cells resistant due to
the overexpression of the MDR1 gene, compound 6 reduced resistance of cells
overexpressing the ABC-type drug transporters CDR1/CDR2 and derivative 18 partially
reversed fluconazole resistance mediated by both types of yeast drug efflux pumps. The
observed effect of sensitization of resistant strains of Candida albicans to fluconazole
activity in the presence of active compounds most likely resulted from inhibition of the
pump-mediated efflux, as was revealed by the results of studies involving the fluorescent
probes, Nile Red, Rhodamine 6G and diS-C3(3).
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Introduction
Opportunistic fungal infections in immunocompromised hosts have become an important
clinical problem, with Candida species remaining one of the leading causes of hospital-acquired
bloodstream infections. The attributable frequency of deaths from candidemia remains close to
40% and Candida albicans comprises nearly half of the isolated fungal pathogens (Pfaller and
Diekema, 2007). The main factors determining high mortality from candidal infections are: a
limited repertoire of clinically used antimycotics and an emerging appearance of drug resistance,
including its multidrug form (Sanglard and Odds, 2002; Pfaller, 2012; Srinivasan et al., 2012).
Among molecular mechanisms underlying multidrug resistance (MDR), the most important is an
overproduction of membrane proteins belonging to the ATP-binding cassette (ABC) transporters
or the major facilitator superfamily (MFS). A number of eﬄux pumps have been identified in
fungi, including Cdr1p, Cdr2p, Mdr1p, and Flu1p in C. albicans (Prasad et al., 2002; Prasad and
Goffeau, 2012). In view of these facts, the search for new antimycotics active against MDR fungi
and/or chemosensitizers, i.e., compounds able to render MDR strains sensitive to clinically used
antifungals, is an urgent need. Chemosensitization has been postulated as one of the ways of
overcoming fungal resistance to the most popular triazole antifungals, including fluconazole (FLC).
Reported examples of compounds effectively chemosensitizing FLC-resistant human pathogenic
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fungi include Cdr1p/Cdr2p–specific curcumin (Sharma et al.,
2009), ibuprofen (Ricardo et al., 2009), or cyclosporine
(Marchetti et al., 2000), inhibitors of MFS-type drug
transporters, like cerulenin analogs (Diwischek et al.,
2009) or synthetic heterocycles containing a cyclobutene-
dione core (Keniya et al., 2015) and clorgyline, targeting
both types of fungal drug eﬄux pumps (Holmes et al.,
2012).
Chalcones, compounds constituting a subclass of flavonoids,
exhibit a number of biological effects, including antimicrobial
activity (Dimmock et al., 1999; Nowakowska, 2007). Antifungal
properties of some chalcones were demonstrated and it was
suggested that the observed activity might be related to the
inhibition of biosynthesis of cell wall components, β(1→3)glucan
and chitin (López et al., 2001). It was also shown that some of the
chalcone derivatives inhibited drug extrusion by the yeast drug
transporters of the ABC type (Conseil et al., 2000; Wink et al.,
2012).
We reported previously that a synthetic oxathiolone fused
chalcone derivative AMG-148 exhibited in antifungal activity
(Ła¸cka et al., 2011). In the present communication, results
of our studies on structural analogs of AMG-148, concerning
especially their chemosensitizing effect on MDR yeast cells, are
described.
Materials and Methods
Compounds and Reagents
The oxathiolone fused chalcone derivatives were synthesized as
described (Konieczny et al., 2007a,b,c). Fluconazole was kindly
provided by Pliva Krakow (Cracow, Poland). All other chemicals
were from Sigma-Aldrich, St. Louis, MO.
Strains and Culture Conditions
The reference strain used in this study was Candida albicans
ATCC 10231. Non-reference strains are listed in Table 1. C.
albicans F2, F5, B3, B4, Gu4, and Gu5 clinical isolates (Franz
et al., 1998, 1999) were kindly provided by J. Morschhäuser,
Würzburg, Germany, while DSY2039 and DSY750 by D.
Sanglard, Lausanne, Switzerland. S. cerevisiae AD1-8u− and
US50-18C mutants AD1-3, AD12, AD13, and AD23 were
kindly provided by A. Goffeau, Louvain-la-Neuve, Belgium. The
AD-derived strains ADCDR1, ADCDR2, and ADMDR1 were
constructed by the previously described methods (Gupta et al.,
1998; Prasad et al., 1998; Smriti et al., 2002). Strains were grown
at 30◦C in Sabouraud medium (2% glucose, 1% yeast extract, and
2% bactopeptone) and stored on Sabouraud plates containing
2% agar.
Susceptibility Testing Procedures
MIC values of tested compounds were determined in RPMI-1640
medium by the slightly modified serial dilution microtiter plate
method recommended by CLSI (Clinical Laboratory Standards
Institute, 2008). Turbidity in individual wells was measured with
a microplate reader (Victor3V, Perkin Elmer). The MIC was
defined as the lowest drug concentration at which at least 80%
TABLE 1 | Non-reference yeast strains used in this study.
Strains Description Source/
references
SACCHAROMYCES CEREVISIAE
US50-18C MATα, PDR1-3, ura3, his1 (parent strain) Balzi et al., 1987
AD1-8u− MATα, PDR1-3, ura3, his1, 1yor1::hisG,
1snq2::hisG, 1pdr5::hisG,
1pdr10::hisG, 1pdr11::hisG,
1ycf1::hisG, 1pdr3::hisG, 1pdr15::hisG
Decottignies et al., 1998
ADCDR1 AD1-8u− transformed with CaCDR1 Smriti et al., 2002
ADCDR2 AD1-8u− transformed with CaCDR2 Smriti et al., 2002
ADMDR1 AD1-8u− transformed with CaMDR1 Gupta et al., 1998
AD1-3 MATα, PDR1-3, ura3, his1, 1yor1::hisG,
1snq2::hisG, 1pdr5::hisG
Decottignies et al., 1998
AD12 MATα, PDR1-3, ura3, his1, 1yor1::hisG,
1snq2::hisG
Decottignies et al., 1998
AD13 MATα, PDR1-3, ura3, his1, 1yor1::hisG,
1pdr5::hisG
Decottignies et al., 1998
AD23 MATα, PDR1-3, ura3, his1,
1snq2::hisG, 1pdr5::hisG
Decottignies et al., 1998
CANDIDA ALBICANS CLINICAL ISOLATES
Gu4 Fluconazole sensitive Franz et al., 1998
Gu5 Fluconazole-resistant due to the
overexpression of CDR1 and CDR2
Franz et al., 1998
F2 Fluconazole sensitive Franz et al., 1999
F5 Fluconazole-resistant due to the
overexpression of CaMDR1 and ERG11
Franz et al., 1999
B3 Fluconazole sensitive Franz et al., 1998
B4 Fluconazole-resistant due to the
overexpression of CaMDR1
Franz et al., 1998
DSY2039 Fluconazole sensitive D.S.a
DSY750 Fluconazole-resistant due to the
overexpression of CaMDR1
D.S.
astrains provided by Dominique Sanglard, Lausanne, Switzerland.
decrease in turbidity, in comparison to the drug-free control, was
observed.
The same conditions were applied for quantification of an
antifungal effect of chalcones in combination with Fluconazole
(FLC), using the checkerboard microdilution assay. The final
concentrations of chalcones ranged from 2 to 64µg/mL for all
chalcones but 11, for which the concentration range was 0.0625
to 2µg/mL. FLC was tested in the 0.03125–8µg/mL range. The
data obtained by the checkerboard microdilution assays were
analyzed using the model-fractional inhibitory concentration
(FIC) index method based on the Loewe theory. The FIC index
is defined as the sum of the MIC of each drug when used in
combination divided by the MIC of the drug used alone. Synergy
and antagonism were defined by FIC indexes of ≤0.5 and >4,
respectively. A FIC index value >0.5 but ≤4 was considered
indifferent (Odds, 2003).
ATPase Activity Assay
The ATPase activity of the plasma membrane fractions was
measured in terms of oligomycin-sensitive release of inorganic
phosphate, as described previously (Smriti et al., 2002), either
alone or in the presence of compounds tested.
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Quantification of Energy-dependent Rhodamine
6G Efflux
Preparation of yeast cells was performed as described previously
(Sharma et al., 2009). Rhodamine 6G (R6G) solution was added
to 1ml aliquots of 2% cell suspension in PBS (to get the 10µM
final concentration of R6G) along with the compound tested
and the mixtures were incubated for 1 h at 30◦C. The cells were
washed twice with PBS and re-energized by re-suspending them
in 1ml of PBS containing 2% glucose and incubated at 30◦C for
30min. After incubation, the samples were centrifuged at 9000×
g for 2min and absorption of the supernatant was measured at
527 nm.
Nile Red Accumulation Assay
The accumulation of Nile Red (NR) was determined by
modification of the method described elsewhere (Ivnitski-Steele
et al., 2009) and measured with a FACSort flow cytometer
(Becton-Dickinson Immunocytometry Systems, San Jose, CA).
Exponential phase yeast cells were collected, washed 3 × with
water and suspended in PBS, pH 7.4, containing 2% glucose to
the final cell density 2% (w/v). The NR solution was added to 1ml
portions of the cell suspension in PBS/glucose to get the 7µM
final concentration of NR, along with the compound tested. After
30min incubation at 30◦C, the samples were excited with a 488-
nm laser and PE–Texas Red filter was used to detect NR-derived
fluorescence. The mean fluorescence intensity was calculated
using the histogram stat program. Analysis was performed with
the CellQuest software (Becton-Dickinson Immunocytometry
Systems).
DiS-C3(3) Accumulation Assay
Fluorescence measurement of diS-C3(3) accumulation in cells
was performed using the procedure described previously
(Hendrych et al., 2009). Briefly, the fluorescent probe diS-C3(3)
(final concentration 2×10−8 M)was added to the cell suspension
10min after compounds tested and fluorescence emission spectra
of the cell suspensions were measured (λex = 531 nm) at the
time of staining. In each experiment, the CD cocktail (5µM
CCCP plus 10µM DM-11) was added, usually after 40min of
staining.
Transmission Electron Microscopy
C. albicans cells from the overnight cultures were harvested,
washed and suspended in Sabouraud medium to the final cell
density of ≈ 106 cfu/mL. The compounds tested were added
and cultures were incubated for 9 h at 30◦C. For ultrastructural
studies, the cells were fixed with 2% glutaraldehyde in 0.1%
phosphate buffer for 3 h at 25◦C, washed with 0.1M phosphate
buffer (pH 7.2) and post-fixed with 1% OsO4 in 0.1M phosphate
buffer for 1 h at 4◦C. Samples were dehydrated with graded
acetone, cleared with toluene, infiltered consequently with
toluene and araldite mixture at room temperature and pure
araldite at 50◦C and finally embedded in an Eppendorff tube with
pure araldite mixture at 60◦C. Semithin and ultrathin section
cutting was done with ultramicrotome (Ultramicotome Lecia EM
UC6). Sections were taken on the 3.05mm diameter, 200 mesh
copper grid, stained with uranyl acetate.
Results
Growth Inhibitory Effect of Chalcone Derivatives
In the previous study, AMG-148, an oxathiolone fused chalcone
derivative, was found to exhibit in vitro antifungal activity against
several strains of human pathogenic yeasts, with MIC values
within the range of 1–16µg/mL and a fungicidal effect was
observed at concentrations 4–32-fold higher than the MICs
(Ła¸cka et al., 2011). In this work, a growth inhibitory effect
of AMG-148 (here compound 11) was compared to that of
its 26 structural analogs, using the serial dilution microtiter
plate method employing C. albicans ATCC 10231 as a reference
microorganism. Results presented in Table 2 indicate that all
compounds but 11 exhibited poor anticandidal activity, with
MICs in the 64 − >256µg/mL range. MIC of the known
antifungal drug FLC in this assay was 2µg/mL.
Combined Antifungal Effect of Chalcone
Derivatives and Fluconazole
Antifungal effect of 11 chalcone derivatives with MIC values ≤
64µg/mL (Table 2) in combination with FLC was quantified
using the checkerboard serial dilution assay. The only case of a
slight synergistic effect was noted for combination of FLC with
compound 11, where a FIC index = 0.22 was determined. For
combinations of all the other 10 chalcones tested with FLC, the
FIC indexes were in the 0.92–1.36 range, thus indicating neither
synergy nor antagonism.
Modulation of Multidrug Resistance
Some natural flavonoids and their synthetic derivatives were
reported to be effective modulators of microbial multidrug
resistance (Ivanova et al., 2008; Liu et al., 2008; Sharma et al.,
2010). To check whether chalcones tested in this work were able
to restore the antifungal potency of FLC against FLC-resistant
human pathogenic yeasts, an in vitro assay was performed
employing C. albicans clinical isolates resistant to fluconazole,
due to the FLC-induced overexpression of genes encoding
multidrug eﬄux pumps. The Gu5 and B4 isolates are FLC-
resistant, due to the documented overexpression of CDR1 and/or
CDR2 in the former and MDR1 in the latter. Their FLC-
sensitive counterparts, Gu4 and B3, respectively, exhibit a basal
expression of these resistance genes. The antifungal activity of
FLC against Candida isolates was determined in the presence
of a fixed concentration of each chalcone. All compounds were
tested at concentrations that did not interfere with fungal growth
(< 1/2MIC; 0.5µg/mL for 11 and 25µg/mL for the other
compounds). Sixteen out of twenty seven chalcones did not show
any effect but the remaining 11 were able to decrease the MICFLC
value of at least one of the FLC-resistant isolates (Table 3).
Eight derivatives demonstrated ability to enhance sensitivity of
C. albicans B4 to FLC. This effect was significant in the case
of compounds 11, 18, and 21. Seven compounds were able to
enhance sensitivity of C. albicans Gu5 to FLC, however this
change was significant only for compounds 6 and 18. The
chemosensitizing efficiency of compounds 6, 18, and 21 is thus
comparable to that of the known chemosensitizers of fungal drug
eﬄux pumps, verapamil and trifuoperazine. On the other hand,
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TABLE 2 | Fungistatic activity of oxathiolone-fused chalcones.
Compound Structure MICa (µg mL−1)
C. albicans
ATCC 10231R1 R2 R3 R4 R5 R6
Type 1
1 −OCH3 −H −H −H −H −H 64
2 −OCH3 −H −H −H −Cl −H 64
3 −OCH3 −H −H −OCH2CH2N(C2H5)2 −H −H 64
4 −OCH2CH2N(C2H5)2 −H −H −H −H −H 128
5 −OCH2CH2N(C2H5)2 −H −H −Br −H −H 128
6 −OCH2CH2N(C2H5)2 −H −H −OCH3 −H −H 64
Type 2
7 −OCH3 −H −H −OCH3 −OCH3 −H >256
8 −OCH3 −H −H −N(CH3)2 −H −H >256
9 −OCH3 −H −H −NO2 −H −H >256
10 −OCH3 −H −H −H −Cl −H >256
11 −OCH3 −H −H −OCH2CH2N(CH3)2 −H −H 2
12 −OCH2CH2N(C2H5)2 −H −H −Cl −H −H 128
13 −OCH2CH2N(C2H5)2 −H −H −H −Cl −H 128
14 −OCH2CH2N(C2H5)2 −H −H −H −H −Cl 128
15 −OCH2CH2N(C2H5)2 −H −H −OCH3 −H −H 64
16 −OCH2CH2N(C2H5)2 −H −H −OCH2CH2N(CH3)2 −H −H 64
17 −OCH2CH2N(C2H5)2 −H −H −H −H 64
18 −OCH3 −H −H −OCH2CH2CH2N(CH3)2 −OCH3 −H 64
19 −OCH2CH2CH3 −H −H −H −H 128
20 −OCH3 −H −H −H −H 128
21 −OCH2CH2CH3 −H −H −OCH2CH2N(CH3)2 −H −H 64
22 −OCH2CH2N(C2H5)2 −H −OCH3 −OCH3 −OCH3 −H 128
23 −OCH2CH2N(C2H5)2 −H −H −OCH3 −OCH3 −H 128
24 −OCH2CH2CH3 −H −H −OCH3 −H −H 128
25 −OCH2CH2CH3 −H −H −OCH3 −OCH3 −H 128
26 −OCH2CH2CH3 −OCH3 −H −OCH3 −H −OCH3 128
27 −OCH2CH2N(CH3)2 −H −H −OCH3 −H −H 64
aMICs were determined in RPMI-1640 buffered medium, as described in Materials and Methods.
the observed substantial reduction of MICFLC of the B4 strain in
presence of 11may result from chemosensitization, but at least in
part could be also attributed to the observed synergism between
FLC and 11 as antifungals.
Several lower concentrations of compounds listed in Table 3
were examined in order to find the lowest concentrations at
which the FLC-sensitizing effect was observed. In the case
of CDR1/CDR2-overexpressing C. albicans Gu5, a two-fold
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TABLE 3 | Influence of chalcones on MICFLC values determined for
Candida albicans clinical isolates.
Compound MIC of FLC (µg/mL)a
B3 B4 Gu4 Gu5
− 1 16 4 256
5 1 4 4 256
6 1 16 4 32
11 0.5 1 2 128
15 1 8 4 64
18 1 2 4 32
19 1 8 4 256
20 1 16 4 128
21 1 2 4 64
22 1 16 4 128
23 1 8 4 128
25 1 8 4 128
VPb 1 0.5 4 64
TFPb 1 1 4 128
aMIC values for FLC were determined by the serial dilution method as described Materials
and Methods, in the presence of a fixed concentration of a compound tested (0.5µg/mL
for 11 and 25µg/mL for the other compounds).
bVerapamil (50µg/mL) and trifluoroperazine (20µg/mL) were used as positive controls.
Cases of significant (>4-fold) MICFLC reduction by a given compound are highlighted in
bold.
TABLE 4 | Activity of compounds 6, 18, 21 and fluconazole against MDR C.
albicans clinical isolates and their drug-sensitive counterparts.
Strain MIC/ICa
50
(µg/mL)
6 18 21 FLC
C. albicans B3 64/38.5 64/40.0 64/42.8 1
C. albicans B4 (MDR1) 64/37.3 64/41.2 64/43.9 16
C. albicans Gu4 32/24.2 64/36.6 64/38.4 4
C. albicans Gu5 (CDR1/CDR2) 64/35.5 64/36.2 64/39.6 256
aMICs and IC50s were determined by using RPMI-1640 buffered medium, as described
in Materials and Methods.
reduction of MICFLC was found for 6 at 5µg/mL, while 18 did
the same at 6.25µg/mL. In the case of C. albicans B4, compounds
21 and 18 caused the twofold reduction of MICFLC at 0.25µg/mL
and 0.1µg/mL, respectively.
Compounds 6, 18, and 21 were also tested for their intrinsic
antifungal activity against FLC-resistant and FLC-sensitive C.
albicans clinical isolates. Comparison of MIC or IC50 values
determined for B3/B4 and Gu4/Gu5 pairs indicates, how
the enhanced activity of a particular transporter affects drug
susceptibility. Data presented in Table 4 confirm resistance
of B4 and Gu5 strains to FLC. On the other hand, the
antifungal activity of chalcones was in most cases not affected
by presence/absence of drug transporters, except for the slight
effect observed for compound 6 in the case of the Gu4/Gu5
pair, while no difference in MIC values was found for 18 and
21. These results suggest that 18 and 21 are not eﬄuxed by
both ABC-type and MFS-type drug transporters of C. albicans,
while 6 may be a poor substrate of Cdr1p or Cdr2p but not of
Mdr1p.
Effect on ATPase Activity of Cdr1p/Cdr2p
The effect of selected compounds (6, 21, and 18) on the
ATPase activity of Cdr1p/Cdr2p was studied by determination
of the oligomycin-sensitive ATP hydrolysis by plasma membrane
preparations isolated from C. albicans Gu5 clinical isolate
overproducing the ABC pumps. No significant reduction of the
ATPase activity in presence of the tested compounds was found
up to 50µg/mL. A very slight reduction, about 20% was noted
for 18 (50µg/mL), however at 25µg/mL the reduction was lower
than 5%. It seems therefore that the oxathiolone-fused chalcones
studied are not inhibitors of the ATPase activity of the ABC-type
C. albicans drug transporters.
Changes in Membrane Potential and Cell
Integrity Monitored with the diS-C3(3) Probe
Using a set of five isogenic mutant strains, the effect of selected
chalcone derivatives on membrane potential and activity of
Pdr5p and Snq2p ABC-type drug exporters in S. cerevisiae was
tested by the fluorescence method, with diS-C3(3) as a probe.
Intracellular accumulation of the probe is accompanied by a
gradual shift of its λmax toward longer wavelengths (red shift),
while any possible eﬄux results in a blue shift. DiS-C3(3) is a
substrate for both Pdr5p and Snq2p (Cˇadek et al., 2004; Hendrych
et al., 2009), so that comparison of the probe accumulation curves
obtained for Pdr5p- and/or Snq2p-expressing and Pdr5p- and
Snq2p-deficient cells measured in the presence of any compound
may provide information about its effect on a given drug eﬄux
pump. On the other hand, analysis of the level of staining of
pump-deficient cells treated with any compound may reveal its
influence on membrane potential, as the blue shift indicates
plasma membrane depolarization, while a red shift is usually a
consequence of hyperpolarization or permeabilization of the cell
membrane. Finally, the cell destruction upon the action of any
compoundmay be confirmed by the consequences of inclusion of
the CD cocktail (5µM CCCP with 10µM DM-11) into the diS-
C3(3) assay. Addition of the lipophilic, weak acid (CCCP) plus
the H+-ATPase blocker (DM-11) results in the rapid blue shift
for the suspension of intact cells, while the shift does not occur if
the cells are broken.
Selected chalcones 6, 11, 18, and 21 were tested in a
broad range of concentrations, from 0.1µM to 20µM. The
representative staining curves obtained for chalcone derivatives
are presented in Figure 1. Cells treated with 11 (Figure 1A)
demonstrated the highest initial rate of staining, indicating
rapidly increasing cell surface permeability for the probe.
It should be noted that the magnitude of the red shift
induced by 11 action on AD1-3 cells (drug eﬄux pump-
free) was concentration-dependent and was observed even at
concentration as low as 0.1µM (graphs not shown). Addition of
the CD cocktail caused lower drop of λmax, indicating partial cell
damage.
Three compounds, 6, 18, and 21, caused hyperpolarization
of the cell membrane but did not damage the cells. Increased
staining of pump-expressing cells after their exposure to
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FIGURE 1 | Effect of selected compounds on the membrane
potential and activity of MDR pumps of S. cerevisiae. Staining
curves of AD1-3 (squares), AD23 (diamonds), AD12 (circles), AD13
(inverted triangles), and US50-18C (triangles) cells. Empty
symbols–no compound added; full symbols–compounds added
10min before diS-C3(3) at following concentrations: 1µM (A),
10µM (B–D). Dotted lines with arrows indicate the addition of the
CD cocktail.
compounds in comparison to chalcone-free controls was caused
by both hyperpolarization and inhibition of the probe export. A
strong inhibition of diS-C3(3) eﬄux by 6 and 11 was observed
in the case of cells expressing Pdr5p or Snq2 (Figures 1A,B),
presence of chalcones 18 and 21 led only to a partial inhibition
of the probe export (Figures 1C,D).
Effect of Chalcone Derivatives on Nile Red
Accumulation
Nile Red (NR) is a fluorogenic substrate of C. albicans
ABC transporters Cdr1p and Cdr2p and the MFS transporter
Mdr1p (Ivnitski-Steele et al., 2009). The probe was used in a
flow cytometry-based assay to measure influence of chalcone
derivatives on NR accumulation in yeast cells. Biological
models used in these studies were: the Saccharomyces cerevisiae
AD1-8u− strain and its fluconazole-resistant transformants:
ADCDR1, ADCDR2, and ADMDR1, along with the matched
pairs of clinical Candida isolates, F2/F5, Gu4/Gu5, and
DSY2039/DSY750. Cells were loaded with NR and levels of
fluorescence derived from NR accumulated by chalcone treated
pump-expressing cells was compared to that of the pump-
deficient cells. As shown in Figure 2, significantly lower level
of NR-derived fluorescence was measured in all resistant cells,
comparing to their pump-deficient counterparts, what indicates
an active eﬄux of NR from the former. The ADMDR1 cells
accumulated approximately tenfold more, the ADCDR2 cells
threefold more and ADCDR1 twofold more of NR in the
presence of compound 18 at 70µM (∼ 28µg/mL) than the AD1-
8u− cells. Significant accumulation NR in ADMDR1 was also
induced by 21. Accumulation of NR in ADCDR1 and ADCDR2
cells remained unaffected by 11. Further studies showed that
21 and 18 at concentrations as low as 0.5µg/mL still strongly
inhibited NR eﬄux from ADMDR1, causing a twofold higher
accumulation of the probe in comparison AD1-8u− (data not
shown). Compound 6 at 70µM caused significant accumulation
of NR exclusively in ADCDR2 and ADCDR1 (2.5 × and 2 ×,
respectively in comparison to AD1-8u−), with no effect on
ADMDR1 (details not shown).
The inhibitory effect of 21 and 18 on MDR1p-mediated
eﬄux was confirmed in the model of clinical Candida isolates.
Compound 21 inhibited NR eﬄux only from the cells of
the F5 and DSY750 strains overexpressing the MDR1 gene,
where respectively fivefold and twofold increase in NR-derived
fluorescence was observed. Surprisingly enough, compound 18
was also found to interfere only with Mdr1p-mediated eﬄux.
In F5 cells, accumulation of NR increased two times and in
DSY750, three times. Both compounds were not able to inhibit
NR eﬄux from Gu5 isolate overproducing Cdr1p and Cdr2p
proteins. Some accumulation of NR in Gu5 but not in F5 and
DS750 was observed in the presence of 6 (details not shown).
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FIGURE 2 | Influence of selected chalcones on Nile Red accumulation in drug efflux pump-free and MDR yeast cells. Cells were incubated for 30min with
Nile Red and chalcones and then fluorescence was measured with a flow cytometer. Values are the means of three independent experiments. Bars represent SD.
Interestingly, in all sensitive strains, presence of 21 resulted in
lower NR accumulation than presence of 18.
Effect of Chalcones on Rhodamine 6G Efflux
In order to get more data characterizing chalcone derivatives
as substrates of membrane multidrug transporters, their effect
on eﬄux from yeast cells of another probe, Rhodamine 6G
(R6G), which is a known substrate of Cdr1p/Cdr2p but not
of the Mdr1p transporter, was investigated. Saccharomyces
cerevisiae ADCDR1, ADCDR2 and control AD1-8u− cells
were first de-energized in presence of 2-deoxy-D-glucose and
2,4-dinitrophenol, then loaded with R6G (final concentration
10µM) along with a compound tested and subsequently activity
of drug-eﬄuxing ABC-type proteins was triggered by glucose
addition. Concentration of the eﬄuxed R6Gwas determined after
30min in supernatants obtained after cell harvesting.
The ADCDR1 and ADCDR2 cells extruded five times
more R6G than the AD1-8u− cells, thus confirming that this
compound is indeed a substrate of the Cdr1p and Cdr2p drug
transporters. Presence of compounds 6, 18, and 21 at 100µM
(∼ 40µg/mL) did not change the amount of R6G released from
AD1-8u− cells. Addition of 21 at 100µM to the suspension of
ADCDR1 or ADCDR2 cells inhibited R6G eﬄux only in about
5 ± 9% and 8 ± 4%, respectively, whereas presence of 6 and 18
at the same concentration resulted in 45 ± 10% and 38 ± 9%
inhibition of the probe eﬄux from ADCDR2 and in 27± 8% and
33 ± 6% inhibition of R6G export from ADCDR1, compared to
the untreated cells. These results corresponded well with those
from the Nile Red assay and showed that compounds 6 and 18
may block to some extent the Cdr1p/Cdr2p-mediated eﬄux from
recombinant S. cerevisiae, while presence of 21 had almost no
effect on the activity of this drug transporter.
Influence of Chalcones on Cell Wall Structure
The effect of selected chalcones on morphology and
ultrastructure of C. albicans cells was investigated using
transmission electron microscopy (TEM). The morphological
alterations observed in cells treated with 6, 11, 18, or 21 at
10µg/mL were documented by microphotographs and some
of these photos are shown in Figure 3. The cross-section of
untreated cells reveals a typical morphology with an intact cell
wall and cytoplasmic membrane, separated by a low-density
space (Figure 3A). Treatment of cells with compounds 6,
18, and 21 did not cause any visible changes, as the cross-
sections of chalcone-treated cells looked very similar to those
of the untreated control (photos not shown). This is not
surprising, since 10µg/mL is well below the MIC value of
these compounds (64µg/mL). On the other hand, 11 induced
significant morphological changes, which ranged from some
discrete alterations to the total destruction of the outer layers
of fungal cells (Figures 3B–D). A common alteration observed
after treatment with compound 11 was a loss of a typical
layered structure and discontinuity or even disappearance of
the cytoplasmic membrane (Figures 3C,D). Other changes
comprised appearance of the irregular cell surfaces, loss of
cell-wall integrity and penetrating lesions of the wall with an
apparent shedding of the cell components (Figure 3C).
Discussion
Three out of 27 chalcones studied in this work (Figure 4)
appeared effective chemosensitizers, able to restore to large
extent sensitivity to fluconazole of MDR C. albicans strains.
Compound 21 effectively chemosensitized cells overexpressing
the MFS-type Mdr1p, compound 6 did the same with cells
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FIGURE 3 | Changes in the cell surface of C. albicans cells observed by
transmission electron microscopy: (A) control cells; (B–D) cells treated
with 11, 10 µg/mL, for 3, 6, and 9h.
FLC-resistant due to the activity of ABC-type drug transporters
and derivative 18 partially reversed fluconazole resistance
mediated by both types of yeast drug eﬄux pumps. This is
worth mentioning that compounds 6, 18, and 21 demonstrated
low in vitro mammalian toxicity against different cell lines
in the tissue cultures (Konieczny et al., 2007a,b,c), what
makes them promising candidates for clinical application
as agents augmenting antifungal chemotherapy with FLC of
infections caused by MDR C. albicans. On the other hand, the
chemosensitizing potential of 11 seems questionable, since this
compound exhibits a strong growth inhibitory and fungicidal
effect at relatively low concentrations. In our previous studies
we provided evidence for inhibition of chitin biosynthesis as
a molecular basis of fungistatic effect of 11 and for inhibition
of β(1→3)glucan synthase resulting in fungicidal action of this
chalcone derivative (Ła¸cka et al., 2011). The latter has been now
confirmed by the loss of continuity of C. albicans cells and the
appearance of the cell wall defects, followed by leakage of cell
components, demonstrated by TEM upon the action of 11 at
concentration well above its MIC and close to the MFC value.
Destruction of S. cerevisiae cells treated with 11, revealed by
the results of experiments involving the diS-C3(3) fluorescent
probe, provides another evidence confirming this hypothesis.
Inhibition of chitin biosynthesis by 11 at concentrations close
to its MIC (Ła¸cka et al., 2011) seems to constitute a molecular
basis for the observed synergism of 11 and FLC, similarly as it
was shown previously for combination of the known inhibitor of
chitin synthase nikkomycin and azole antifungals (Milewski et al.,
1991).
It is not clear why the chemosensitizing potency of 6, 18,
and 21 is much better than that of their other close structural
analogs tested by us. The only characteristic common structural
pattern observed here is presence of the 4′-dimethylaminoalkoxy
FIGURE 4 | Structures of chemosensitizers of MDR yeasts selected in
this study.
substituent in ring B (compounds 11, 16, 18, and 21) that seems
beneficial for the chemosensitizing efficacy (18 and 21) or high
antifungal activity (11) of type 2 oxathiolone fused chalcones but
this effect is abolished when the similar substituent is also present
in the A ring (16).
Results of experiments employing Rhodamine 6G and Nile
Red showed that some chalcones studied effectively interfered
with extrusion of the fluorescent probes by the ABC and/or
MFS proteins. Compounds 18 and 6 inhibited the eﬄux of
Nile Red by Cdr1p, Cdr2p, and Mdr1p, export of Rhodamine
6G by the Cdr1p and Cdr2p transporters and eﬄux of diS-
C3(3) from the S. cerevisiae strain overexpressing PDR5. On
the other hand, 21 did not affect the Rhodamine 6G and Nile
Red eﬄux mediated by Cdr1p/Cdr2p eﬄux and poorly affected
export of diS-C3(3) from S. cerevisiae strains overexpressing
PDR5 and/or SNQ2, while it effectively inhibited the eﬄux
of Nile Red from strains overexpressing MDR1. An inhibitory
effect of 6 on Pdr5p- and Snq2p-mediated eﬄux of the diS-
C3(3) probe and a very slight inhibition of the Cdr1p/Cdr2p-
derived ATPase activity under in vitro conditions indicates its
possible inhibitory activity against different ABC-type yeast
drug transporters, probably not resulting from interaction with
the ATP-binding domains. Previously it was shown that 4-
alkoxychalcones (structure different from that of compounds
described in this study) bind to the ATP binding site and to the
steroid binding site of mammalian ABC-type drug transporter
P-glycoprote (Conseil et al., 1998). It is possible therefore that
compound 6may also bind tomore than one site in the ABC-type
yeast drug transporters.
The fact that some chalcones effectively prevented extrusion
of particular fluorescent probes from MDR C. albicans cells and
chemosensitized MDR cells to FLC but on the other hand, their
intrinsic anticandidal activity against FLC-resistant MDR cells,
was very similar or the same as against FLC-sensitive cells, may
indicate that these compounds bind to the MDR proteins outside
their substrate-binding sites and prevent binding of probes or
fluconazole to these sites but are not effectively extruded by
the drug eﬄux pumps. In summary, the observed effect of
sensitization of resistant strains of Candida albicans to FLC in the
presence of chalconic chemosensitizers, most likely results from
a non-competitive inhibition of drug eﬄux proteins, especially
those of theMFS-type, although this hypothesis should be further
verified.
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